Title |
Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
|
---|---|
Published in |
Frontiers in Pharmacology, May 2018
|
DOI | 10.3389/fphar.2018.00365 |
Pubmed ID | |
Authors |
Muthu K. Shanmugam, Kwang S. Ahn, Jong H. Lee, Radhamani Kannaiyan, Nurulhuda Mustafa, Kanjoormana A. Manu, Kodappully S. Siveen, Gautam Sethi, Wee J. Chng, Alan P. Kumar |
Abstract |
Several lines of evidence have demonstrated that deregulated activation of NF-κB plays a pivotal role in the initiation and progression of a variety of cancers including multiple myeloma (MM). Therefore, novel molecules that can effectively suppress deregulated NF-κB upregulation can potentially reduce MM growth. In this study, the effect of celastrol (CSL) on patient derived CD138+ MM cell proliferation, apoptosis, cell invasion, and migration was investigated. In addition, we studied whether CSL can potentiate the apoptotic effect of bortezomib, a proteasome inhibitor in MM cells and in a xenograft mouse model. We found that CSL significantly reduced cell proliferation and enhanced apoptosis when used in combination with bortezomib and upregulated caspase-3 in these cells. CSL also inhibited invasion and migration of MM cells through the suppression of constitutive NF-κB activation and expression of downstream gene products such as CXCR4 and MMP-9. Moreover, CSL when administered either alone or in combination with bortezomib inhibited MM tumor growth and decreased serum IL-6 and TNF-α levels. Overall, our results suggest that CSL can abrogate MM growth both in vitro and in vivo and may serve as a useful pharmacological agent for the treatment of myeloma and other hematological malignancies. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 7 | 35% |
Other | 3 | 15% |
Professor > Associate Professor | 2 | 10% |
Researcher | 2 | 10% |
Student > Ph. D. Student | 1 | 5% |
Other | 1 | 5% |
Unknown | 4 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Unspecified | 7 | 35% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Medicine and Dentistry | 2 | 10% |
Social Sciences | 1 | 5% |
Other | 1 | 5% |
Unknown | 5 | 25% |